Latest Conference Articles

February 24th 2020, 6:06am

Transplantation and Cellular Therapy Meetings

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

February 23rd 2020, 2:28am

Transplantation and Cellular Therapy Meetings

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

February 23rd 2020, 2:20am

Transplantation and Cellular Therapy Meetings

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

February 23rd 2020, 2:12am

Transplantation and Cellular Therapy Meetings

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

February 23rd 2020, 2:00am

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

February 22nd 2020, 2:14am

Transplantation and Cellular Therapy Meetings

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

February 22nd 2020, 12:58am

Transplantation and Cellular Therapy Meetings

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

February 22nd 2020, 12:45am

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

February 22nd 2020, 12:36am

Transplantation and Cellular Therapy Meetings

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

February 21st 2020, 9:38pm

Transplantation and Cellular Therapy Meetings

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

February 21st 2020, 9:19pm

Transplantation and Cellular Therapy Meetings

Carlos R. Bachier, MD, discusses the toxicity profile of lisocabtagene maraleucel that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

February 21st 2020, 7:12pm

Transplantation and Cellular Therapy Meetings

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

February 21st 2020, 3:23am

Transplantation and Cellular Therapy Meetings

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

February 20th 2020, 10:57pm

Transplantation and Cellular Therapy Meetings

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

February 20th 2020, 8:47pm

Transplantation and Cellular Therapy Meetings

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

February 11th 2020, 1:55am

PER® Winter Lung Cancer Conference

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

February 11th 2020, 1:30am

SGO Winter Meeting

Chemotherapy in combination with immunotherapy holds promise in the treatment paradigm for patients with ovarian cancer, Floor Backes, MD, said at the 2020 SGO Winter Meeting.

February 11th 2020, 12:17am

SGO Winter Meeting

Robert L. Coleman, MD, FACOG, FACS, discusses the role of rucaparib as a treatment option for patients with ovarian cancer, how this agent compares with other PARP inhibitors in this space, and where research is headed for these agents.

February 10th 2020, 11:20pm

PER® Winter Lung Cancer Conference

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

February 10th 2020, 11:20pm

PER® Winter Lung Cancer Conference

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.